These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

3148 related articles for article (PubMed ID: 7804530)

  • 1. Enhancement of immune reactivity in the lymph nodes draining a murine melanoma engineered to elaborate interleukin-4.
    Krauss JC; Strome SE; Chang AE; Shu S
    J Immunother Emphasis Tumor Immunol; 1994 Aug; 16(2):77-84. PubMed ID: 7804530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generation of T-cells reactive to the poorly immunogenic B16-BL6 melanoma with efficacy in the treatment of spontaneous metastases.
    Geiger JD; Wagner PD; Cameron MJ; Shu S; Chang AE
    J Immunother Emphasis Tumor Immunol; 1993 Apr; 13(3):153-65. PubMed ID: 8471590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2.
    Yoshizawa H; Chang AE; Shu S
    J Immunol; 1991 Jul; 147(2):729-37. PubMed ID: 1830072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cross-reactivity of anti-CD3/IL-2 activated effector cells derived from lymph nodes draining heterologous clones of a murine tumor.
    Matsumura T; Krinock RA; Chang AE; Shu S
    Cancer Res; 1993 Sep; 53(18):4315-21. PubMed ID: 8364926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic efficacy of T cells derived from lymph nodes draining a poorly immunogenic tumor transduced to secrete granulocyte-macrophage colony-stimulating factor.
    Arca MJ; Krauss JC; Aruga A; Cameron MJ; Shu S; Chang AE
    Cancer Gene Ther; 1996; 3(1):39-47. PubMed ID: 8785710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells.
    Tanaka H; Yoshizawa H; Yamaguchi Y; Ito K; Kagamu H; Suzuki E; Gejyo F; Hamada H; Arakawa M
    J Immunol; 1999 Mar; 162(6):3574-82. PubMed ID: 10092816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specific immunotherapy with tumour-draining lymph node cells cultured with both anti-CD3 and anti-CD28 monoclonal antibodies.
    Harada M; Okamoto T; Omoto K; Tamada K; Takenoyama M; Hirashima C; Ito O; Kimura G; Nomoto K
    Immunology; 1996 Mar; 87(3):447-53. PubMed ID: 8778032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cellular interactions in effector cell generation and tumor regression mediated by anti-CD3/interleukin 2-activated tumor-draining lymph node cells.
    Yoshizawa H; Chang AE; Shu SY
    Cancer Res; 1992 Mar; 52(5):1129-36. PubMed ID: 1531321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adoptive immunotherapy with tumor-specific T lymphocytes generated from cytokine gene-modified tumor-primed lymph node cells.
    Ohno K; Yoshizawa H; Tsukada H; Takeda T; Yamaguchi Y; Ichikawa K; Maruyama Y; Suzuki Y; Suzuki E; Arakawa M
    J Immunol; 1996 May; 156(10):3875-81. PubMed ID: 8621926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation of therapeutic T-lymphocytes after in vivo tumor transfection with an allogeneic class I major histocompatibility complex gene.
    Wahl WL; Strome SE; Nabel GJ; Plautz GE; Cameron MJ; San H; Fox BA; Shu S; Chang AE
    J Immunother Emphasis Tumor Immunol; 1995 Jan; 17(1):1-11. PubMed ID: 7728301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of interleukin-1 alpha on the in vitro activation of tumor-draining lymph node cells for adoptive immunotherapy.
    Hammel JM; Tuck MK; Hain JM; Chang AE; Sondak VK
    J Immunother Emphasis Tumor Immunol; 1994 Jul; 16(1):1-12. PubMed ID: 8081555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ex vivo activation of tumor-draining lymph node T cells reverses defects in signal transduction molecules.
    Liu J; Finke J; Krauss JC; Shu S; Plautz GE
    Cancer Immunol Immunother; 1998 Jul; 46(5):268-76. PubMed ID: 9690455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel role for autologous tumour cell vaccination in the immunotherapy of the poorly immunogenic B16-BL6 melanoma.
    Geiger JD; Wagner PD; Shu S; Chang AE
    Surg Oncol; 1992 Jun; 1(3):199-208. PubMed ID: 1341252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sensitizing T-lymphocytes for adoptive immunotherapy by vaccination with wild-type or cytokine gene-transduced melanoma.
    Lipshy KA; Kostuchenko PJ; Hamad GG; Bland CE; Barrett SK; Bear HD
    Ann Surg Oncol; 1997 Jun; 4(4):334-41. PubMed ID: 9181234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of intracranial tumors by systemic transfer of superantigen-activated tumor-draining lymph node T cells.
    Inoue M; Plautz GE; Shu S
    Cancer Res; 1996 Oct; 56(20):4702-8. PubMed ID: 8840987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Depletion of CD4+ CD25+ regulatory cells augments the generation of specific immune T cells in tumor-draining lymph nodes.
    Tanaka H; Tanaka J; Kjaergaard J; Shu S
    J Immunother; 2002; 25(3):207-17. PubMed ID: 12000862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation by anti-CD3 of tumor-draining lymph node cells for specific adoptive immunotherapy.
    Yoshizawa H; Sakai K; Chang AE; Shu SY
    Cell Immunol; 1991 May; 134(2):473-9. PubMed ID: 1827049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stimulation of tumor-draining lymph node cells with superantigenic staphylococcal toxins leads to the generation of tumor-specific effector T cells.
    Shu S; Krinock RA; Matsumura T; Sussman JJ; Fox BA; Chang AE; Terman DS
    J Immunol; 1994 Feb; 152(3):1277-88. PubMed ID: 8301131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo antitumor efficacy of tumor-draining lymph node cells activated with nonspecific T-cell reagents.
    Shu S; Sussman JJ; Chang AE
    J Immunother Emphasis Tumor Immunol; 1993 Nov; 14(4):279-85. PubMed ID: 8280709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diverse manifestations of tumorigenicity and immunogenicity displayed by the poorly immunogenic B16-BL6 melanoma transduced with cytokine genes.
    Arca MJ; Krauss JC; Strome SE; Cameron MJ; Chang AE
    Cancer Immunol Immunother; 1996 May; 42(4):237-45. PubMed ID: 8665571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 158.